TY - JOUR
T1 - Markers for Guillain-Barré syndrome with poor prognosis
T2 - a multi-center study
AU - Yamagishi, Yuko
AU - Suzuki, Hidekazu
AU - Sonoo, Masahiro
AU - Kuwabara, Satoshi
AU - Yokota, Takanori
AU - Nomura, Kyoichi
AU - Chiba, Atsuro
AU - Kaji, Ryuji
AU - Kanda, Takashi
AU - Kaida, Kenichi
AU - Ikeda, Shu Ichi
AU - Mutoh, Tatsuro
AU - Yamasaki, Ryo
AU - Takashima, Hiroshi
AU - Matsui, Makoto
AU - Nishiyama, Kazutoshi
AU - Sobue, Gen
AU - Kusunoki, Susumu
PY - 2017/12
Y1 - 2017/12
N2 - Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.
AB - Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85037710422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037710422&partnerID=8YFLogxK
U2 - 10.1111/jns.12234
DO - 10.1111/jns.12234
M3 - Article
C2 - 28833828
AN - SCOPUS:85037710422
VL - 22
SP - 433
EP - 439
JO - Journal of the Peripheral Nervous System
JF - Journal of the Peripheral Nervous System
SN - 1085-9489
IS - 4
ER -